Search

Author/Creator Schlichting, D.

2. FRI0123 SAFETY PROFILE OF BARICITINIB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS UP TO 8.4 YEARS: AN UPDATED INTEGRATED SAFETY ANALYSIS. (2nd June 2020)

Authors:
Genovese, M. C.; Smolen, J. S.; Takeuchi, T.; Burmester, G. R.; Deberdt, W.; Schlichting, D.; Song, H.; Mo, D.; Walls, C.; Winthrop, K.
Journal:
Annals of the rheumatic diseases
Issue:
Volume 79(2020)Supplement 1
Page Start:
642
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. LB0001 Baricitinib, an Oral Janus Kinase (JAK)1/JAK2 Inhibitor, in Patients with Active Rheumatoid Arthritis (RA) and An Inadequate Response to CDMARD Therapy: Results of the Phase 3 RA-Build Study. (9th June 2015)

Authors:
Dougados, M.; van der Heijde, D.; Chen, Y.-C.; Greenwald, M.; Drescher, E.; Liu, J.; Beattie, S.; de la Torre, I.; Rooney, T.; Schlichting, D.; de Bono, S.; Emery, P.
Journal:
Annals of the rheumatic diseases
Issue:
Volume 74(2015)Supplement 2
Page Start:
79
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. LB0005 12-week results of a phase 2B dose-ranging study of LY3009104 (INCB028050), an oral JAK1/JAK2 inhibitor, in combination with traditional dmards in patients with rheumatoid arthritis. (23rd January 2014)

Authors:
Keystone, E.; Taylor, P.; Genovese, M.; Schlichting, D.; Beattie, S.; Gaich, C.; Fidelus Gort, R.; Luchi, M.; Macias, W.L.
Journal:
Annals of the rheumatic diseases
Issue:
Volume 71(2012)Supplement 3
Page Start:
152
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. OP0029 Baricitinib, An Oral Janus Kinase (JAK)1/JAK2 Inhibitor, in Patients with Active Rheumatoid Arthritis (RA) and an Inadequate Response to TNF Inhibitors: Results of the Phase 3 RA-Beacon Study. (9th June 2015)

Authors:
Genovese, M.C.; Kremer, J.; Zamani, O.; Ludivico, C.; Krogulec, M.; Xie, L.; Beattie, S.; Koch, A.E.; Cardillo, T.; Rooney, T.; Macias, W.; Schlichting, D.; Smolen, J.S.
Journal:
Annals of the rheumatic diseases
Issue:
Volume 74(2015)Supplement 2
Page Start:
75
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. SAT0349 Patient-Reported Outcomes from a Phase 3 Study of Baricitinib in Patients with Rheumatoid Arthritis (RA) and an Inadequate Response to Tumor Necrosis Factor Inhibitors. (9th June 2015)

Authors:
Smolen, J.S.; Kremer, J.; Gaich, C.; DeLozier, A.M.; Schlichting, D.; Xie, L.; Genovese, M.C.
Journal:
Annals of the rheumatic diseases
Issue:
Volume 74(2015)Supplement 2
Page Start:
785
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. THU0168 Baricitinib Inhibits Radiographic Progression of Structural Joint Damage at 1 Year in Patients with Rheumatoid Arthritis (RA) and An Inadequate Response To csDMARDs. (15th July 2016)

Authors:
van der Heijde, D.; Dougados, M.; Chen, Y.-C.; Greenwald, M.; Drescher, E.; Klar, R.; Xie, L.; de la Torre, I.; Rooney, T.P.; Witt, S.; Schlichting, D.; DeBono, S.; Emery, P.
Journal:
Annals of the rheumatic diseases
Issue:
Volume 75(2016)Supplement 2
Page Start:
244
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗